NYSE - Nasdaq Real Time Price
USD
Zimmer Biomet Holdings, Inc. (ZBH)
82.83
-0.18
(-0.22%)
At close: 4:00:03 PM EDT
82.83
0.00
(0.00%)
After hours: 4:15:08 PM EDT
Trade ZBH on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for ZBH
- Previous Close
83.01 - Open
83.72 - Bid 83.07 x 20000
- Ask 83.09 x 20000
- Day's Range
82.56 - 84.49 - 52 Week Range
79.83 - 108.29 - Volume
1,944,808 - Avg. Volume
2,351,541 - Market Cap (intraday)
16.024B - Beta (5Y Monthly) 0.47
- PE Ratio (TTM)
21.46 - EPS (TTM)
3.86 - Earnings Date Apr 28, 2026
- Forward Dividend & Yield 0.96 (1.16%)
- Ex-Dividend Date Mar 31, 2026
- 1y Target Est
98.52
Recent News: ZBH
View More
Performance Overview: ZBH
Trailing total returns as of 5/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
ZBH
7.63%
S&P 500 (^GSPC)
7.59%
1-Year Return
ZBH
9.29%
S&P 500 (^GSPC)
31.36%
3-Year Return
ZBH
38.30%
S&P 500 (^GSPC)
78.06%
5-Year Return
ZBH
48.63%
S&P 500 (^GSPC)
75.29%
Earnings Trends: ZBH
View MoreAnalyst Insights: ZBH
View MoreStatistics: ZBH
View MoreValuation Measures
As of 5/4/2026
-
Market Cap
16.05B
-
Enterprise Value
23.09B
-
Trailing P/E
21.42
-
Forward P/E
9.90
-
PEG Ratio (5yr expected)
0.59
-
Price/Sales (ttm)
1.94
-
Price/Book (mrq)
1.26
-
Enterprise Value/Revenue
2.74
-
Enterprise Value/EBITDA
9.98
Financial Highlights
Profitability and Income Statement
-
Profit Margin
9.05%
-
Return on Assets (ttm)
4.10%
-
Return on Equity (ttm)
6.07%
-
Revenue (ttm)
8.41B
-
Net Income Avi to Common (ttm)
761.2M
-
Diluted EPS (ttm)
3.86
Balance Sheet and Cash Flow
-
Total Cash (mrq)
478.5M
-
Total Debt/Equity (mrq)
59.83%
-
Levered Free Cash Flow (ttm)
1.04B
Compare To: ZBH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: ZBH
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports: ZBH
View More-
Zimmer Biomet Earnings: Decent Quarterly Results Aren't Enough to Assuage Investor Worries
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
RatingPrice Target -
Zimmer Biomet Earnings: Solid Organic Growth and Acquisitions Add Up to Strong Quarter
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
RatingPrice Target -
Zimmer Biomet Earnings: Solid Organic Growth and Acquisitions Add Up to Strong Quarter
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
RatingPrice Target -
Restructuring to drive long-term growth
Based in Warsaw, Indiana, Zimmer Biomet is the nation's largest pure-play maker of orthopedic devices. The current company arose from the 2015 merger of Zimmer and Biomet, both of which were headquartered in Warsaw, Indiana. The company designs, develops, and manufactures reconstructive orthopedic implants, sports injury repair and trauma products, and related orthopedic surgical products. Its primary customers include musculoskeletal surgeons, neurosurgeons, hospitals, distributors, and, in their capacity as agents, healthcare purchasing organizations or buying groups. ZBH shares are a component of the S&P 500.
RatingPrice Target
